These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

143 related articles for article (PubMed ID: 36038734)

  • 21. Apoptosis may be an early event of progestin therapy for endometrial hyperplasia.
    Amezcua CA; Lu JJ; Felix JC; Stanczyk FZ; Zheng W
    Gynecol Oncol; 2000 Nov; 79(2):169-76. PubMed ID: 11063639
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Role of progesterone in endometrial cancer.
    Kim JJ; Chapman-Davis E
    Semin Reprod Med; 2010 Jan; 28(1):81-90. PubMed ID: 20104432
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Up-regulation of nuclear receptor corepressor (NCoR) in progestin-induced growth suppression of endometrial hyperplasia and carcinoma.
    Kashima H; Horiuchi A; Uchikawa J; Miyamoto T; Suzuki A; Ashida T; Konishi I; Shiozawa T
    Anticancer Res; 2009 Apr; 29(4):1023-9. PubMed ID: 19414341
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [Effects of pathological assessment of endometrial tissue in fertility-sparing treatment with progestin for endometrial carcinoma of stage I a and complex atypical hyperplasia].
    Gong Q; Chen X; Xie X
    Zhonghua Fu Chan Ke Za Zhi; 2014 Sep; 49(9):664-9. PubMed ID: 25487452
    [TBL] [Abstract][Full Text] [Related]  

  • 25. PTEN as a predictive marker of response to conservative treatment in endometrial hyperplasia and early endometrial cancer. A systematic review and meta-analysis.
    Travaglino A; Raffone A; Saccone G; Insabato L; Mollo A; De Placido G; Zullo F
    Eur J Obstet Gynecol Reprod Biol; 2018 Dec; 231():104-110. PubMed ID: 30342311
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Molecular tools to reestablish progestin control of endometrial cancer cell proliferation.
    Dai D; Kumar NS; Wolf DM; Leslie KK
    Am J Obstet Gynecol; 2001 Apr; 184(5):790-7. PubMed ID: 11303185
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Dual-specificity phosphatase 6 predicts the sensitivity of progestin therapy for atypical endometrial hyperplasia.
    Zhang H; Yan L; Bai Y; Li C; Guo Q; Wang C; Zhao X; Li M
    Gynecol Oncol; 2015 Mar; 136(3):549-53. PubMed ID: 25451692
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Phosphorylation of IDH1 Facilitates Progestin Resistance in Endometrial Cancer.
    Li J; Qin Z; Li Y; Huang B; Xiao Q; Chen P; Luo Y; Zheng W; Zhang T; Zhang Z
    Adv Sci (Weinh); 2024 Jun; 11(23):e2310208. PubMed ID: 38582508
    [TBL] [Abstract][Full Text] [Related]  

  • 29. ABX-1431 inhibits the development of endometrial adenocarcinoma and reverses progesterone resistance by targeting MGLL.
    Ma X; Xia M; Wei L; Guo K; Sun R; Liu Y; Qiu C; Jiang J
    Cell Death Dis; 2022 Dec; 13(12):1067. PubMed ID: 36550099
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Fertility preserving management of early endometrial cancer in a patient cohort at the department of women's health at the university of Tuebingen.
    Andress J; Pasternak J; Walter C; Kommoss S; Krämer B; Hartkopf A; Brucker SY; Schönfisch B; Steinmacher S
    Arch Gynecol Obstet; 2021 Jul; 304(1):215-221. PubMed ID: 33606091
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [Outcome analysis of conservative treatment of well-differentiated endometrial adenocarcinoma and severe atypical hyperplasia in young women].
    Yu M; Shen K; Yang JX; Huang HF; Wu M; Pan LY; Lang JH; Lian LJ
    Zhonghua Fu Chan Ke Za Zhi; 2006 Apr; 41(4):242-5. PubMed ID: 16759458
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Should progesterone and estrogen receptors be assessed for predicting the response to conservative treatment of endometrial hyperplasia and cancer? A systematic review and meta-analysis.
    Raffone A; Travaglino A; Saccone G; Mollo A; De Placido G; Insabato L; Zullo F
    Acta Obstet Gynecol Scand; 2019 Aug; 98(8):976-987. PubMed ID: 30779338
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Effect of oral versus intrauterine progestins on weight in women undergoing fertility preserving therapy for complex atypical hyperplasia or endometrial cancer.
    Cholakian D; Hacker K; Fader AN; Gehrig PA; Tanner EJ
    Gynecol Oncol; 2016 Feb; 140(2):234-8. PubMed ID: 26706662
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Down-regulation of bcl-2 is a potential marker of the efficacy of progestin therapy in the treatment of endometrial hyperplasia.
    Amezcua CA; Zheng W; Muderspach LI; Felix JC
    Gynecol Oncol; 1999 Apr; 73(1):126-36. PubMed ID: 10094893
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Fertility-Sparing Management Using Progestin for Young Women with Endometrial Cancer From a Population-Based Study.
    Kim SR; van der Zanden C; Ikiz H; Kuzelijevic B; Havelock J; Kwon JS
    J Obstet Gynaecol Can; 2018 Mar; 40(3):328-333. PubMed ID: 28986185
    [TBL] [Abstract][Full Text] [Related]  

  • 36. National patterns of care and fertility outcomes for reproductive-aged women with endometrial cancer or atypical hyperplasia.
    Harrison RF; He W; Fu S; Zhao H; Sun CC; Suidan RS; Woodard TL; Rauh-Hain JA; Westin SN; Giordano SH; Meyer LA
    Am J Obstet Gynecol; 2019 Nov; 221(5):474.e1-474.e11. PubMed ID: 31128110
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Oncologic and reproductive outcomes after fertility-sparing management with oral progestin for women with complex endometrial hyperplasia and endometrial cancer.
    Chen M; Jin Y; Li Y; Bi Y; Shan Y; Pan L
    Int J Gynaecol Obstet; 2016 Jan; 132(1):34-8. PubMed ID: 26493012
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The fertility-sparing treatment in patients with endometrial atypical hyperplasia and early endometrial cancer: a debated therapeutic option.
    Gadducci A; Spirito N; Baroni E; Tana R; Genazzani AR
    Gynecol Endocrinol; 2009 Oct; 25(10):683-91. PubMed ID: 19562604
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Prognostic factors of oncological and reproductive outcomes in fertility-sparing treatment of complex atypical hyperplasia and low-grade endometrial cancer using oral progestin in Chinese patients.
    Zhou R; Yang Y; Lu Q; Wang J; Miao Y; Wang S; Wang Z; Zhao C; Wei L
    Gynecol Oncol; 2015 Dec; 139(3):424-8. PubMed ID: 26428941
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Progestin therapy for endometrial cancer: the potential of fourth-generation progestin (review).
    Banno K; Kisu I; Yanokura M; Tsuji K; Masuda K; Ueki A; Kobayashi Y; Yamagami W; Nomura H; Susumu N; Aoki D
    Int J Oncol; 2012 Jun; 40(6):1755-62. PubMed ID: 22366992
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.